| Abstract | Long-term survival after treatment for childhood cancers has dramatically improved in the past 25 years. Overall 5-year survival rates for childhood cancer are greater than 70%. Residual endocrine disorders are as high as 40% in this population, with the most serious disturbances noted in growth and thyroid function. Dysfunction also is observed in the hypothalamic-pituitary-adrenal axis and the hypothalamic-pituitary-gonadal axis, and recent evidence cites alterations in bone and mineral metabolism, body composition, and lipid disorders. These abnormalities are most likely related directly to prior cancer treatment. This chapter focuses on a description of such disorders and offers suggestions for long-term endocrine management and follow-up evaluation. |
| Authors | Sharon E Oberfield, Charles A Sklar
(Affiliation: College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.)
|
| Journal | Adolescent medicine (Philadelphia, Pa.)
(Adolesc Med)
Vol. 13
Issue 1
Pg. 161-9, viii
(Feb 2002)
ISSN: 1041-3499 United States |
| PMID | 11841962
(Publication Type: Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Adolescent
- Child
- Child Development
(drug effects)
- Endocrine System Diseases
(drug therapy, etiology)
- Human Growth Hormone
(adverse effects, deficiency, therapeutic use)
- Humans
- Neoplasm Recurrence, Local
(chemically induced, prevention & control)
- Neoplasms
(complications)
- Risk Factors
- Survivors
|
